Download Melanoma Bridge 2015

PRELIMINARY PROGRAM
MELANOMA BRIDGE 2015
Hotel Excelsior, Naples, Italy
Sala Partenope
December 1-4, 2015
December 1st
Opening Ceremony
5:00 PM
Opening Ceremony with "patients meet the experts" Session
December 2nd
Molecular and Immuno advances
Chairpersons: Gerardo Botti, Ena Wang
9:30 AM
Michael Davies
9:55 AM
10:20 AM
Michael Krauthammer
Roger Lo
10:45 AM
Gennaro Ciliberto
11:10 AM
11:25 AM
Break
Stefani Spranger
11:50 AM
12:15 PM
12:40 PM
Cassian Yee
Dung Le*
Discussion
1:25 PM
Lunch
Immunologic and metabolic consequences of
PI3K/AKT/mTOR activation in melanoma
Insights from Sequencing the Melanoma Exome
Genomic, epigenomic and immune evolution of melanoma
acquiring resistance to MAPK-targeted therapies
Non-mutational adaptive changes in melanoma cells exposed
to BRAF and MEK inhibitors help the establishment of drug
resistance
Tumor-intrinsic beta-catenin signaling mediates tumorimmune avoidance
Endogenous T Cell Therapy: The next generation
Combination Therapies
Chairpersons: Paolo A. Ascierto, Claus Garbe
2:25 PM
Sandra Demaria
Harnessing radiotherapy to improve responses to
immunotherapy in cancer
2:50 PM
Samir Khleif
New Strategies in Combination Immune Therapy
3:15 PM
Yang Xin Fu
Targeting tumor tissue to increase innate sensing for
immunotherapy
3:40 PM
Reinhard Dummer
Biomarkers for treatment decision?
4:05 PM
Break
4:20 PM
Igor Puzanov
Combining oncolytic therapies in the era of checkpoint
inhibitors
4:45 PM
Steve O'Day
Combination therapy in melanoma-for whom?
3P Solution S.r.l. a socio unico. Sede Legale: via Marradi 3, 20123 Milano. Capitale sociale: 10000,00€. P.IVA/CF 06860060968 Iscrizione
REA MI n.1919426.
5:10 PM
Michael Postow
Immune checkpoint blockade for melanoma: Should we
combine or sequence ipilimumab and PD-1 antibody
therapy?
5:35 PM
Nicola Mozzillo
Surgery as a therapeutic option in metastatic stage IV
melanoma
6:00 PM
6:45 PM
Roundtable
Conclusions
December 3rd
News on Immunotherapy
Chairpersons: Michele Maio, Giuseppe Palmieri
9:00 AM
Ahmad Tarhini
An update on adjuvant and neoadjuvant
9:25 AM
Sanjiv Agarwala
Overview of intralesional oncolytic therapy
9:50 AM
Alexander Eggermont
Update on adjuvant ipilimumab EORTC18071, update on
ongoing adjuvant pembrolizumab EORTC1325 trials
10:15 AM
Sponsored Symposium*
11:15 AM
Break
11:30 AM
Hassane Zarour
Targeting multiple inhibitory pathways in melanoma
11:55 AM
Howard Kaufman*
12:20 PM
David Stroncek
Improving Adoptive Immune Therapy using Genetically
Engineered T cells
12:45 PM
Discussion
1:30 PM
Lunch
Tumor Microenvironment and Biomarkers
Chairpersons: Giuseppe Masucci, Alessandro Testori
2:30 PM
Soldano Ferrone
Grp94 and BRAF inhibitor resistance
2:55 PM
Thomas Gajewski
Tumor and host factors mediating resistance to
immunotherapy
3:20 PM
Janis M. Taube
Multiparameter pathologic assessment of the PD-1/PD-L1
pathway in melanoma
3:45 PM
4:10 PM
4:25 PM
Jennifer A. Wargo
Break
Bernard A. Fox
4:50 PM
Licia Rivoltini
5:15 PM
5:40 PM
Magdalena Thurin
Maria Libera Ascierto
6:05 PM
6:50 PM
Roundtable
Conclusions
Developing Cancer Immunotherapy Strategies that Change
the Tumor Microenvironment and Eliminate Cancer
Myeloid cells and tumor exosomes: a crosstalk for assessing
immunosuppression?
Response and resistance to PD-1 pathway blockade: clues
from the tumor microenvironment
3P Solution S.r.l. a socio unico. Sede Legale: via Marradi 3, 20123 Milano. Capitale sociale: 10000,00€. P.IVA/CF 06860060968 Iscrizione
REA MI n.1919426.
December 4th
World-Wide Immunoscore Task Force: an Update
Chairpersons: Paolo A. Ascierto, Francesco M. Marincola, Jerome Galon
9:30 AM
Jerome Galon
Immunoscore in the era of cancer immunotherapy
9:50 AM
Paolo A. Ascierto
Immunoscore and immunoprofiling in melanoma
10:10 AM
Alessandro Lugli
The immunoscore in colorectal cancer highlights the
importance of digital scoring systems in surgical pathology
10:30 AM
10:45 AM
11:05 AM
11:25 AM
11:45 AM
Break
Carlo Bifulco
Giuseppe Masucci
Magdalena Thurin
Franck Pages
12:05 PM
12:50 PM
Roundtable
Conclusions
1:05 PM
Lunch
Next generation immunoprofiling
In search of personalized cancer immunotherapy
The immunoscore : toward an integrated
immunomonitoring from the diagnosis to the follow up of
cancer’s patients
Economic Sustainability of melanoma treatments: Regulatory, Health Technology Assessment and
Market Access issues
Chairpersons: Paolo A. Ascierto, Pier Luigi Canonico
2:05 PM
FDA representative
2:25 PM
Jorge Camarero (EMA)
Nivolumab, the regulatory experience in immunotherapy
2:45 PM
Paolo Foggi (AIFA)
3:05 PM
Deborah Morrison (NICE)
3:25 PM
Break
3:40 PM
Claudio Jommi
Evidence to optimize access for melanoma drugs
4:00 PM
Francesco de Lorenzo
4:20 PM
Patients representatives
Valerie Guild (AIM at Melanoma); Fondazione Melanoma
4:40 PM
Roundtable
Americo Cicchetti*, Paola Queirolo*, AIOM Representative
5:25 PM
Conclusions
* To be confirmed
3P Solution S.r.l. a socio unico. Sede Legale: via Marradi 3, 20123 Milano. Capitale sociale: 10000,00€. P.IVA/CF 06860060968 Iscrizione
REA MI n.1919426.
FACULTY
MELANOMA BRIDGE 2015
December 1-4, 2015
Sanjiv
Agarwala
St. Luke's University Hospital and Temple University,
Bethlehem, Pennsylvania
Maria Libera
Ascierto
Kimmel Cancer Center, Johns Hopkins School of Medicine,
Baltimore, Maryland
Paolo A.
Ascierto
Unit of Melanoma, Cancer Immunotherapy and Innovative
Therapy, National Cancer Institute “Fondazione G. Pascale” of
Naples, Italy
Carlo
Bifulco
Earle A. Chiles Research Institute, Robert W. Franz Cancer
Research Center, Providence Portland Medical Center,
Portland, Oregon
Gerardo
Botti
National Cancer Institute “Fondazione G. Pascale” of Naples,
Italy
Jorge
Camarero
Oncology Area, Spanish Agency for Medicines and Medical
Devices, AEMPS, Spain
Oncology assessor at the European Medicines Agency, EMA
Pier Luigi
Canonico
Department of Scienze del Farmaco, University of Piemonte
Orientale, Novara, Italy
Gennaro
Ciliberto
National Cancer Institute “Fondazione G. Pascale” of Naples,
Italy
Michael
Davies
Department of Melanoma Medical Oncology, Department of
Systems Biology, University of Texas MD Anderson Cancer
Center, Texas
Francesco
de Lorenzo
Italian Federation of Volunteer-based Cancer Organizations,
FAVO
Sandra
Demaria
New York University School of Medicine and NYU Langone
Medical Center Alexandria Center for Life Sciences, New York
Reinhard
Dummer
University of Zurich Hospital, Department of Dermatology,
Zurich
Alexander
Eggermont
Institut de Cancérologie Gustave Roussy, Villejuif, Paris-Sud,
France
Soldano
Ferrone
Massachusetts General Hospital, Boston, Massachusetts
Paolo
Foggi*
Italian Medicines Agency, AIFA
Bernard A.
Fox
Earle A. Chiles Research Institute, Robert W. Franz Cancer
Research Center, Providence Portland Medical Center,
Portland, Oregon
Yang Xin
Fu
Donnelley Biological Sciences Learning Center, University of
3P Solution S.r.l. a socio unico. Sede Legale: via Marradi 3, 20123 Milano. Capitale sociale: 10000,00€. P.IVA/CF 06860060968 Iscrizione
REA MI n.1919426.
Chicago, Illinois
Thomas F.
Gajewski
Department of Pathology and Department of Medicine,
Section of Hematology/Oncology, Chicago, Illinois
Jerome
Galon
INSERM (National Institute of Health and Medical Research),
Paris, France
Claus
Garbe
Division of Dermatologic Oncology Department of
Dermatology Eberhard Karls University Tuebingen, Germany
Valerie
Guild
AIM at Melanoma, Richmond, California
Claudio
Jommi
Department of Pharmaceutical Sciences, University of
Piemonte Orientale, Novara, Italy
Samir
Khleif
Georgia Regents University Cancer Center, Augusta, Georgia
John M.
Kirkwood
Melanoma and Skin Cancer Program University of Pittsburgh
Cancer Institute, Pennsylvania
Michael
Krauthammer
Yale University School of Medicine, New Haven, Connecticut
Roger
Lo
Melanoma Clinic in Dermatology Member, Jonsson
Comprehensive Cancer Center David Geffen School of
Medicine at UCLA, Los Angeles, California
Alessandro
Lugli
Institute of Pathology, University of Bern, Switzerland
Michele
Maio
Division of Medical Oncology and Immunotherapy,
Department of Oncology, University Hospital of Siena, Italy
Francesco M.
Marincola
Sidra Medical and Research Center, Doha, Qatar
Giuseppe
Masucci
Department of Oncology-Pathology, Karolinska Institute,
Stockholm, Sweden
Deborah
Morrison
National Institute for Health and Care Excellence, NICE
Nicola
Mozzillo
Department Melanoma and Soft Tissues, National Cancer
Institute “Fondazione G. Pascale” of Naples, Italy
Steven
O'Day
The Los Angeles Skin Cancer Institute, The Beverly Hills Cancer
Institute in Beverly Hills, California
Franck
Pages
Service d'Immunologie Biologique, Hôpital Européen Georges
Pompidou, Paris, France
Giuseppe
Palmieri
Unit of Cancer Genetics, Institute of Biomolecular Chemistry,
National Research Council, Sassari, Italy
Michael
Postow
Memorial Sloan Kettering Cancer Center, New York
Igor
Puzanov
Division of Hematology-Oncology, Vanderbilt University
Medical Center, Nashville, Tennessee
Licia
Rivoltini
National Cancer Institute of Milan, Italy
Paola
Queirolo
National Institute for Cancer Research, Genova, Italy
3P Solution S.r.l. a socio unico. Sede Legale: via Marradi 3, 20123 Milano. Capitale sociale: 10000,00€. P.IVA/CF 06860060968 Iscrizione
REA MI n.1919426.
Stefani
Spranger
Department of Patholog, University of Chicago, Illinois
David Frank
Stroncek
Department of Transfusion Medicine, NIH Clinical Center,
Bethesda, Maryland
Ahmad
Tarhini
Melanoma and Skin Cancer Program University of Pittsburgh
Cancer Institute, Pennsylvania
Janis M.
Taube
Johns Hopkins University SOM, Baltimore, Maryland
Alessandro
Testori
Dermato-oncology Surgery Division, European Institute of
Oncology, Milan, Italy
Magdalena
Thurin
Cancer Diagnosis Program, Division of Cancer Treatment and
Diagnosis, NCI, NIH, Rockville, Maryland
Ena
Wang
Sidra Medical and Research Centre, Doha, Qatar
Jennifer A.
Wargo
Department of Surgical Oncology, The University of Texas MD
Anderson Cancer Center, Houston, Texas
Cassian
Yee
Solid Tumor Cell Therapy and ACT Platform, UT MD Anderson
Cancer Center, Texas
Hassane
Zarour
University of Pittsburgh Cancer Institute Hillman Cancer
Center, Pennsylvania
3P Solution S.r.l. a socio unico. Sede Legale: via Marradi 3, 20123 Milano. Capitale sociale: 10000,00€. P.IVA/CF 06860060968 Iscrizione
REA MI n.1919426.